We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 16, 2005
Last Update Posted: May 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Christopher Ryan, OHSU Knight Cancer Institute

RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well giving calcitriol together with mitoxantrone and prednisone works in treating patients with metastatic prostate cancer.

Condition Intervention Phase
Prostate Cancer Dietary Supplement: calcitriol Drug: mitoxantrone hydrochloride Drug: prednisone Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of DN-101 (High Dose Pulse Calcitriol), Mitoxantrone, Prednisone in Androgen-Independent Prostate Cancer (AIPC)

Resource links provided by NLM:

Further study details as provided by Christopher Ryan, OHSU Knight Cancer Institute:

Primary Outcome Measures:
  • Reduction in serum prostate-specific antigen (PSA) by 50% measured every 21 days

Secondary Outcome Measures:
  • Toxicity as measured by Common Toxicity Criteria v3.0
  • Frozen plasma and serum samples for correlative biomarker analysis collected every 21 days
  • Confirmed PSA reduction > 75% measured every 21 days
  • PSA normalization (< 4 ng/mL) measured every 21 days
  • Response to measurable disease as measured by RECIST criteria every 9 weeks
  • Analgesic response as measured by McGill-Melzack Pain Questionnaire every 21 days
  • Analgesic medication use decreased by ≥ 50% without an increase in pain for 2 consecutive evaluations at least 3 weeks apart
  • Palliative response as measured by McGill-Melzack Pain Questionnaire every 21 days
  • Quality of life as measured by EORTC core questionnaire Quality of Life-C30 every 21 days
  • Time to palliative-progression as measured by McGill-Melzack Pain Questionnaire every 21 days
  • Time to PSA progression measured every 21 days
  • Time to progression in measurable or evaluable disease as measured by whole body scan and/or CT or MRI scan every 9-12 weeks
  • Time to death assessed every 6 months after completion of study treatment

Enrollment: 19
Study Start Date: September 2004
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the prostate-specific antigen (PSA) response rate, defined as the fraction of patients with 50% reduction in PSA level over 3 weeks' time, in patients with androgen-independent metastatic prostate cancer treated with high-dose pulse calcitriol, mitoxantrone, and prednisone.


  • Determine the safety and tolerability of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral high dose pulse calcitriol on day 1, mitoxantrone IV on day 2, and oral prednisone on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed prostate cancer

    • Androgen-independent disease, defined as disease progression while on standard hormonal management, including antiandrogen withdrawal

      • Patients must continue primary hormonal therapy during study treatment
    • Regional or distant metastases
  • Prostate-specific antigen > 5 ng/mL
  • No brain metastases



  • 18 to 100

Performance status

  • ECOG 0-3

Life expectancy

  • Not specified


  • Adequate hematologic function


  • Adequate hepatic function


  • Adequate renal function
  • No calcium-salt kidney stones within the past 5 years
  • No hypercalcemia


  • Adequate cardiac function
  • No significant cardiac disease
  • No atrial fibrillation


  • Fertile patients must use effective barrier contraception during and for 2 months after completion of study treatment
  • No other serious medical illness
  • No other active malignancy except nonmelanoma skin cancer


Biologic therapy

  • More than 28 days since prior biologic therapy


  • No prior chemotherapy

Endocrine therapy

  • See Disease Characteristics


  • No prior strontium chloride Sr 89
  • More than 28 days since prior radiotherapy
  • More than 56 days since prior samarium Sm 153 lexidronam pentasodium


  • Prior prostatectomy and/or orchiectomy allowed


  • More than 28 days since prior investigational therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00182741

United States, Oregon
Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States, 97239-3098
Sponsors and Collaborators
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Study Chair: Christopher W. Ryan, MD OHSU Knight Cancer Institute
  More Information

Responsible Party: Christopher Ryan, Principal Investigator, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT00182741     History of Changes
Other Study ID Numbers: CDR0000441172
First Submitted: September 15, 2005
First Posted: September 16, 2005
Last Update Posted: May 3, 2017
Last Verified: May 2017

Keywords provided by Christopher Ryan, OHSU Knight Cancer Institute:
recurrent prostate cancer
stage IV prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Calcium Channel Agonists
Membrane Transport Modulators
Vasoconstrictor Agents
Growth Substances